Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1968 1
1972 1
1973 2
1974 5
1975 2
1976 3
1977 1
1978 4
1979 2
1980 1
1981 1
1982 4
1983 4
1984 5
1985 5
1986 13
1987 9
1988 24
1989 14
1990 15
1991 20
1992 21
1993 21
1994 35
1995 25
1996 36
1997 32
1998 51
1999 54
2000 38
2001 39
2002 61
2003 49
2004 44
2005 65
2006 62
2007 52
2008 64
2009 78
2010 63
2011 67
2012 93
2013 96
2014 88
2015 107
2016 88
2017 99
2018 98
2019 73
2020 101
2021 89
2022 74
2023 85
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

1,982 results

Results by year

Filters applied: . Clear all
Page 1
Thrombotic Microangiopathy and the Kidney.
Brocklebank V, Wood KM, Kavanagh D. Brocklebank V, et al. Clin J Am Soc Nephrol. 2018 Feb 7;13(2):300-317. doi: 10.2215/CJN.00620117. Epub 2017 Oct 17. Clin J Am Soc Nephrol. 2018. PMID: 29042465 Free PMC article. Review.
Hemolytic Uremic Syndrome.
Cody EM, Dixon BP. Cody EM, et al. Pediatr Clin North Am. 2019 Feb;66(1):235-246. doi: 10.1016/j.pcl.2018.09.011. Pediatr Clin North Am. 2019. PMID: 30454746 Review.
Hemolytic uremic syndrome (HUS) is the clinical triad of thrombocytopenia, anemia, and acute kidney injury. ...
Hemolytic uremic syndrome (HUS) is the clinical triad of thrombocytopenia, anemia, and acute kidney injury. ...
Haemolytic uraemic syndrome.
Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Fakhouri F, et al. Lancet. 2017 Aug 12;390(10095):681-696. doi: 10.1016/S0140-6736(17)30062-4. Epub 2017 Feb 25. Lancet. 2017. PMID: 28242109 Review.
How I diagnose and treat atypical hemolytic uremic syndrome.
Fakhouri F, Schwotzer N, Frémeaux-Bacchi V. Fakhouri F, et al. Blood. 2023 Mar 2;141(9):984-995. doi: 10.1182/blood.2022017860. Blood. 2023. PMID: 36322940 Free article.
Our understanding and management of atypical hemolytic uremic syndrome (aHUS) have dramatically improved in the last decade. aHUS has been established as a prototypic disease resulting from a dysregulation of the complement alternative C3 convertase. ...
Our understanding and management of atypical hemolytic uremic syndrome (aHUS) have dramatically improved in the last de …
Complement-driven hemolytic uremic syndrome.
Leon J, LeStang MB, Sberro-Soussan R, Servais A, Anglicheau D, Frémeaux-Bacchi V, Zuber J. Leon J, et al. Am J Hematol. 2023 May;98 Suppl 4:S44-S56. doi: 10.1002/ajh.26854. Am J Hematol. 2023. PMID: 36683290 Free article. Review.
Overactivation of the complement alternative pathway drives the pathogenesis of primary atypical hemolytic uremic syndrome (aHUS). Genetically-determined or acquired dysregulation of the complement is frequently identified in patients with aHUS, pregnancy-rel …
Overactivation of the complement alternative pathway drives the pathogenesis of primary atypical hemolytic uremic syndrome
Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill.
Manrique-Caballero CL, Peerapornratana S, Formeck C, Del Rio-Pertuz G, Gomez Danies H, Kellum JA. Manrique-Caballero CL, et al. Crit Care Clin. 2020 Apr;36(2):333-356. doi: 10.1016/j.ccc.2019.11.004. Epub 2020 Jan 31. Crit Care Clin. 2020. PMID: 32172817 Review.
Hemolytic uremic syndrome is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. ...Development of clinical prediction scores and rapid diagnostic tests for hemolytic uremic syndrome based on mec
Hemolytic uremic syndrome is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney inj
An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Frémeaux-Bacchi V; HUS International. Loirat C, et al. Pediatr Nephrol. 2016 Jan;31(1):15-39. doi: 10.1007/s00467-015-3076-8. Epub 2015 Apr 11. Pediatr Nephrol. 2016. PMID: 25859752 Review.
Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. ...
Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulati …
Haemolytic uraemic syndrome.
Michael M, Bagga A, Sartain SE, Smith RJH. Michael M, et al. Lancet. 2022 Nov 12;400(10364):1722-1740. doi: 10.1016/S0140-6736(22)01202-8. Epub 2022 Oct 19. Lancet. 2022. PMID: 36272423 Review.
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment.
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group. Ariceta G, et al. Kidney Int. 2021 Jul;100(1):225-237. doi: 10.1016/j.kint.2020.10.046. Epub 2020 Dec 8. Kidney Int. 2021. PMID: 33307104 Free article. Clinical Trial.
Secondary endpoints included change in hematologic parameters and kidney function. 18 patients with a median age of 5.2 years were evaluated. At baseline, symptoms of atypical hemolytic uremic syndrome outside the kidney were present in 72.2% of patients and …
Secondary endpoints included change in hematologic parameters and kidney function. 18 patients with a median age of 5.2 years were evaluated …
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
Here we evaluate the efficacy and safety of ravulizumab in adults with atypical hemolytic uremic syndrome presenting with thrombotic microangiopathy. ...Thus, treatment with ravulizumab once every eight weeks resulted in rapidly improved hematologic and renal …
Here we evaluate the efficacy and safety of ravulizumab in adults with atypical hemolytic uremic syndrome presenting wi …
1,982 results